Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg

Table 2 Characteristics of chemotherapy

Treatment characteristics	n (%)
Median duration of first-line therapy (range), d	105 (6-568)
First-line therapy
Single-agent (Fluoropyrimidine)	3 (5.5)
Doublet	47 (85.5)
FLO	38 (69.1)
FLP	2 (3.6)
XP	2 (3.6)
FOLFIRI	2 (3.6)
Other	3 (5.5)
Triplet	5 (9.1)
EOX	2 (3.6)
FLOT	2 (3.6)
TFLP	1 (1.8)
Oxaliplatin-based therapy	42 (76.4)
Cisplatin-based therapy	7 (12.7)
Other therapy	6 (10.9)
Trastuzumab containing therapy	5 (9.1)
Participation in clinical trial	3 (5.5)
Toxicities with dosage reduction	31 (56.4)
Polyneuropathy HematotoxicityLeucopeniaThrombopenia	14 (25.5) 6 (10.9)3 (5.5)3 (5.5)
Fatigue	4 (7.3)
Nausea	4 (7.3)
Other	3 (5.5)
Toxicities with interruption of treatment	6 (10.9)
Polyneuropathy	2 (3.6)
Fatigue	2 (3.6)
Anaphylaxia	1 (1.8)
Infection	1 (1.8)
Second-line treatment	28 (50.9)

FLO: 5-Fluorouracil (5-FU), leucovorin, oxaliplatin; FLP: 5-FU, leucovorin, cisplatin; XP: Capecitabine, cisplatin; FOLFIRI: 5-FU, leucovorin, irinotecan; EOX: Epirubicin, oxaliplatin, capecitabine; FLOT: 5-FU, leucovorin, oxaliplatin, docetaxel; TFLP: Docetaxel, 5-FU, leucovorin, cisplatin.